文献速递复苏、休克与脓毒症呼吸衰竭与机械通气重症综合管理与镇静镇痛

恢复期血浆治疗住院COVID-19患者(RECOVERY):一项随机对照开放标签平台试验

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.
PubMed 文献 · Lancet · 2021-05-14
一句话结论住院COVID-19患者中,高滴度恢复期血浆未改善28天生存(24% vs 24%,率比1.00,95%CI 0.93-1.07;p=0.95)。

RECOVERY平台试验在英国177家NHS医院纳入住院COVID-19患者,1:1随机分配至仅常规治疗组或常规治疗加高滴度恢复期血浆组,主要终点为意向性治疗分析的28天死亡率。2020年5月28日至2021年1月15日,16287例入组患者中11558例(71%)符合血浆治疗条件并纳入分析。恢复期血浆组5795例中1399例(24%)死亡,常规治疗组5763例中1408例(24%)死亡(率比1.00,95%CI 0.93-1.07;p=0.95),所有预设亚组(包括随机化时未检出SARS-CoV-2抗体的患者)结果相似。28天出院比例(66% vs 66%;率比0.99,95%CI 0.94-1.03;p=0.57)及未行有创机械通气者进展至有创机械通气或死亡的复合终点(29% vs 29%;率比0.99,95%CI 0.93-1.05;p=0.79)均无显著差异,高滴度恢复期血浆未改善生存或其他预设临床结局。

要点

  • 住院COVID-19患者中,高滴度恢复期血浆与仅常规治疗相比28天死亡率无显著差异:24%(1399/5795)vs 24%(1408/5763),率比1.00(95%CI 0.93-1.07),p=0.95。
  • 28天出院比例两组均为66%(3832/5795 vs 3822/5763),率比0.99(95%CI 0.94-1.03),p=0.57,血浆未加快出院。
  • 随机化时未行有创机械通气者中,进展至有创机械通气或死亡的复合终点两组均为29%(1568/5493 vs 1568/5448),率比0.99(95%CI 0.93-1.05),p=0.79。
  • 28天死亡率率比在所有预设亚组中相似,包括随机化时未检出SARS-CoV-2抗体的患者。

适用人群与场景

  • 英国177家NHS医院收治的住院COVID-19患者,入组RECOVERY试验并签署知情同意。
  • 16287例入组患者中11558例(71%)符合接受恢复期血浆的条件,被随机分配至恢复期血浆组或仅常规治疗组。

处置流程与药物剂量

  • 符合条件并签署知情同意的患者按1:1随机分配至仅常规治疗组或常规治疗加高滴度恢复期血浆组。
  • 主要终点为28天死亡率,按意向性治疗原则分析。

研究设计与关键结果

  • 随机对照、开放标签平台试验(RECOVERY),在英国177家NHS医院开展;2020年5月28日至2021年1月15日,16287例入组患者中11558例(71%)符合血浆治疗条件并纳入分析。
  • 主要终点28天死亡率:恢复期血浆组24%(1399/5795)vs 常规治疗组24%(1408/5763),率比1.00(95%CI 0.93-1.07),p=0.95,无显著差异。
  • 28天死亡率率比在所有预设亚组中相似,包括随机化时未检出SARS-CoV-2抗体的患者。
  • 28天出院:恢复期血浆组66%(3832/5795)vs 常规治疗组66%(3822/5763),率比0.99(95%CI 0.94-1.03),p=0.57,无显著差异。
  • 随机化时未行有创机械通气者进展至有创机械通气或死亡的复合终点:恢复期血浆组29%(1568/5493)vs 常规治疗组29%(1568/5448),率比0.99(95%CI 0.93-1.05),p=0.79,无显著差异。

证据类型、等级与局限

  • 证据类型:随机对照、开放标签平台试验(RECOVERY);试验注册号ISRCTN 50189673、ClinicalTrials.gov NCT04381936。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,住院COVID-19患者中高滴度恢复期血浆未改善生存或其他预设临床结局;原文未据此给出推荐。

指南或共识出处

  • RECOVERY(Randomised Evaluation of COVID-19 Therapy)平台试验;资助:UK Research and Innovation(Medical Research Council)与National Institute of Health Research。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19.

METHODS: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936.

FINDINGS: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93-1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94-1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93-1·05; p=0·79).

INTERPRETATION: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes.

FUNDING: UK Research and Innovation (Medical Research Council) and National Institute of Health Research.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet. 2021. PMID: 34000257. doi:10.1016/S0140-6736(21)00897-7

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。